Saum Ghodoussipour, MD
Urology · Los Angeles, CANPI 1003298019
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.8%), consulting fees and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Urogen Pharma, Inc. at 42.3% of the total. Among urology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 88 payments — averaging $686.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Urogen Pharma, Inc.$26K
- Intuitive Surgical$13K
- Janssen Research & Development, LLC$7K
- KARL Storz Endoscopy-america$6K
- Janssen Scientific Affairs, LLC$4K
- Ferring Pharmaceuticals Inc.$3K
- plus $1K from 9 others
Across 49 payments — averaging $21,908 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$443K
- Janssen Research & Development, LLC$419K
- E.r. Squibb & Sons, L.L.C.$211K
What the payments were for
- Consulting fees$20,87935%
- Speaking & faculty fees$22,82038%
- Travel & lodging$4,0457%
- Food & beverage$3,1555%
- Education$9,53516%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Urogen Pharma, Inc. | 19 | $25,545 |
| Intuitive Surgical | 30 | $12,577 |
| Janssen Research & Development, LLC | 8 | $7,205 |
| KARL Storz Endoscopy-america | 6 | $5,853 |
| Janssen Scientific Affairs, LLC | 5 | $4,452 |
| Ferring Pharmaceuticals Inc. | 3 | $3,458 |
| Koelis Inc. | 6 | $636 |
| EDAP Technomed Inc | 4 | $257 |
| Immunitybio, Inc. | 1 | $136 |
| Photocure Inc | 1 | $119 |
| Astellas Pharma US Inc | 1 | $78 |
| Merck | 1 | $44 |
| AstraZeneca | 1 | $35 |
| Boston Scientific | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JELMYTO$17,427
- Da Vinci Surgical System$7,767
- ZUSDURI$5,972
- DA VINCI SP$4,500
- ADSTILADRIN$3,351
- Erleada$2,449
- TRINITY$527
- ANKTIVA$136
- HOPKINS$119
- Cysview$119
How this compares
$60,434 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 45 | $542 |
| Solifenacin Succinate | 27 | $482 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $212 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $163 |
| Finasteride | 11 | $105 |
| Gabapentin | 12 | $17 |
Paid to pharmacies, not to this prescriber.
Other urology in Los Angeles
- Arie BelldegrunLos Angeles$1.8M
- Mihir DesaiLos Angeles$1.5M
- Stuart HoldenLos Angeles$1.1M
- William AronsonLos Angeles$540K
- Amir LebastchiLos Angeles$478K
- Nazy ZomorodianLos Angeles$309K
- Jeffrey Loh-DoyleLos Angeles$308K
- Siamak DaneshmandLos Angeles$306K
- Karim ChamieLos Angeles$291K
- Brian ShuchLos Angeles$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.